This article's lead is ready for translation. Click for more information.

Olutasidenib

From WikiProjectMed
Jump to navigation Jump to search
Olutasidenib
Names
Trade namesRezlidhia
Other namesFT-2102
Clinical data
Drug classIDH1 inhibitor[1]
Main usesAcute myeloid leukemia[1]
Side effectsNausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, diarrhea[1]
Routes of
use
By mouth
Typical dose150 mg BID[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC18H15ClN4O2
Molar mass354.79 g·mol−1
3D model (JSmol)
  • C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2
  • InChI=InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
  • Key:NEQYWYXGTJDAKR-JTQLQIEISA-N

Olutasidenib, sold under the brand name Rezlidhia, is an medication used to treat acute myeloid leukemia.[1] Specifically it is used in those with certain IDH1 mutations who have failed other treatments.[1] It is taken by mouth.[1]

Common side effects include nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, and diarrhea.[1] Common lab abnormalities include high potassium, low sodium, liver problems, and kidney problems.[1] Other side effects may include differentiation syndrome.[1] It is an isocitrate dehydrogenase-1 (IDH1) inhibitor.[1]

Olutasidenib was approved for medical use in the United States in 2022.[1] In the United States it costs about 32,200 USD per month as of 2022.[4]

Medical uses

Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.[2][3][5]

Dosage

It is taken at a dose of 150 mg twice per day.[1]

Society and culture

Names

Olutasidenib is the international nonproprietary name.[6]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "REZLIDHIA™ (olutasidenib) capsules, for oral use". Archived from the original on 15 January 2023. Retrieved 15 January 2023. Archived 15 January 2023 at the Wayback Machine
  2. 2.0 2.1 "Archive copy" (PDF). Archived (PDF) from the original on 2022-12-13. Retrieved 2022-12-20.{{cite web}}: CS1 maint: archived copy as title (link) Archived 2022-12-13 at the Wayback Machine
  3. 3.0 3.1 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215814Orig1s000ltr.pdf Archived 2022-12-20 at the Wayback Machine Public Domain This article incorporates text from this source, which is in the public domain.
  4. "Optum Rx Revenue Grows 9% in 2022". Formulary Watch. Archived from the original on 15 January 2023. Retrieved 15 January 2023. Archived 15 January 2023 at the Wayback Machine
  5. "FDA approves olutasidenib". U.S. Food and Drug Administration (FDA). 1 December 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022. Archived 20 December 2022 at the Wayback Machine
  6. World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

External links

External sites:
Identifiers: